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Summary
Objective: The purpose of our study was to determine what variables were associated with ven-
tricular ﬁbrillation (VF) induced during electrophysiological stimulation test in patients without
apparent organic heart disease.
Methods: Our study evaluated 77 patients (51± 15 years) who underwent electrophysiological
stimulation test, signal averaging, and Na+ channel-blocker challenge test (pilsicainide test).
The subjects were divided into two groups, the Brugada group and non-Brugada group. Further,
the patients were divided into three subgroups on the base of symptoms (8, 7 symptomatic;
9, 13 syncope; 28, 12 asymptomatic group; in the Brugada and non-Brugada groups, respec-
tively). Multivariate analyses evaluated the association between baseline clinical factors and
the induction of VF.
Results: The inducibility of VF was signiﬁcantly (p < 0.0001) higher in the Brugada group (n = 33,
73%) than the non-Brugada group (n = 4, 13%). The multivariate analysis demonstrated that
symptoms (odds ratio (OR) 31.6; 95% conﬁdence interval (CI): 2.3—430.6; p < 0.01), type 1
electrocardiogram after pilsicainide test (OR 21.3; CI: 1.7—272.2; p < 0.02), and syncope (OR
13.5; CI: 1.2—158.8; p < 0.05) were strongly associated with the inducibility of VF, but not with
family history, type 1 electrocardiogram in control, positive in late potential, maxST elevation
(200V) after pilsicainide test.
∗ Corresponding author. Tel.: +81 836 22 2856; fax: +81 836 22 2856.
E-mail address: ashimizu@yamaguchi-u.ac.jp (A. Shimizu).
0914-5087/$ — see front matter © 2010 Published by Elsevier Ireland Ltd on behalf of Japanese College of Cardiology.
doi:10.1016/j.jjcc.2010.01.006
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Conclusions: The symptoms, syncope, and type 1 electrocardiogram after pilsicainide test were
independently associated with the electrophysiological substrate of VF in patients without appar-
Ireland Ltd on behalf of Japanese College of Cardiology.
I
V
o
w
H
d
R
d
a
[
i
c
J
g
e
d
t
N
c
o
B
e
i
b
d
V
[
o
s
l
[
e
a
a
A
E
B
s
i
t
t
p
a
V
a
a
m
r
a
M
S
O
t
s
n
f
t
t
d
w
s
a
[
V
h
f
e
S
l
o
l
a
r
S
T
t
u
a
w
a
u
a
r
p
l
b
o
h
m
s
s
vation) in at least two of the three right precordial leads
(V1—V3) in the standard right precordial leads (V1—V3), orent heart disease.
© 2010 Published by Elsevier
ntroduction
entricular ﬁbrillation (VF) is one of the important etiologies
f sudden cardiac death and occurs commonly in patients
ith organic heart disease and left ventricular dysfunction.
owever, VF occurs even in patients without apparent heart
isease, which is so-called idiopathic ventricular ﬁbrillation.
ecently, idiopathic VF has been classiﬁed as Brugada syn-
rome [1—7], long QT syndrome [8], short QT syndrome [9],
nd catecholaminergic polymorphic ventricular tachycardia
10], and others, based on their speciﬁc clinical character-
stics.
Brugada syndrome is a relatively frequent disease asso-
iated with VF in patients without apparent heart disease in
apan and Asia [5]. It is also associated with electrocardio-
raphic abnormality of the right bundle branch block with ST
levation in the right precordial leads [1—7]. The electrocar-
iogram (ECG) ﬁndings are the most useful parameters for
he diagnosis of the Brugada type ECG [5]. Furthermore, the
a+ channel-blockers challenge test is also useful because it
an unmask the Brugada type ECG and induce the elevation
f the ST-segment in patients with intermittent or concealed
rugada syndrome [5,6].
Although several parameters, such as the ECG ﬁndings,
lectrophysiological stimulation test (EPS), signal averag-
ng, T-wave alternance (TWA), and abnormal genes have
een reported to be predictive values for sudden cardiac
eath [7,11—15], the speciﬁcity of the induction test of
T (ventricular tachycardia)/VF during EPS remains unclear
13,14]. Since there is a wide variation in the incidence
f events [7,16,17], the appropriate risk stratiﬁcation for
udden cardiac death remains uncertain. A recently pub-
ished second consensus report on the Brugada syndrome
18] from Europe and the USA implied that patients with
ither spontaneous or drug-induced type 1 Brugada ECG and
history of syncope or sudden cardiac death should have
n implantable cardioverter deﬁbrillator (ICD) implanted.
symptomatic patients with a spontaneous type 1 Brugada
CG or asymptomatic patients with a drug-induced type 1
rugada ECG and a family history of sudden cardiac death
hould undergo EPS to guide the selection of patients for ICD
mplantation.
In Japan, the inducibility of VF is one of the factors
o make a decision of implantation of ICD according to
he guidelines on ICD [19] or Brugada syndrome [20]. It is
resumed that the inducibility of VF in patients without
pparent organic heart disease indicates the existence of
F substrate. However, it is still unclear what variables are
ssociated with VF induced during EPS in patients without
pparent organic heart disease. Therefore, we performed a
ultivariate analysis to clarify what variables were strongly
elated to the inducibility of VF in patients without any
pparent organic heart disease.
o
c
t
o
nethods
ubjects
ur study evaluated 77 patients who underwent EPS for
he diagnosis of arrhythmia, risk stratiﬁcation in Brugada
yndrome, and/or sudden cardiac death in patients with
o apparent heart disease and normal left ventricular
unction between January 2005 and August 2008. In addi-
ion, they underwent ECGs, Na+ channel-blocker challenge
ests, signal averaging, coronary angiography, and car-
iac echocardiography during their hospitalization. Patients
ith idiopathic ventricular tachycardia (Ca antagonist sen-
itive) [21], long QT syndrome [8], short QT syndrome [9],
nd catecholaminergic polymorphic ventricular tachycardia
10] were excluded. Furthermore, those with spontaneous
F induced by ischemia, electrolyte disturbance, and/or
ypothermia were also excluded.
A diagnosis of Brugada type ECG was made based on the
ollowing criteria: (1) J point amplitude over 0.2mV with
ither spontaneous or drug-induced type 1 ECG (coved type
T elevation) in at least two of the three right precordial
eads in the standard right precordial leads (V1—V3), or one
r two intercostal spaces above the standard right precordial
eads. Three types of repolarization patterns were deﬁned
s type 1, type 2, and type 3 according to the consensus
eport [5]. Type 1 is characterized by a prominent coved
T-segment elevation displaying J wave amplitude 2mm.
ype 2 also has a high take-off ST-segment elevation, but in
his case J wave amplitude (2mm) gives rise to a grad-
ally descending ST-segment elevation (remaining 1mm
bove the baseline), followed by a positive or biphasic T-
ave that results in a saddle back conﬁguration. Type 3 has
J wave amplitude (2mm) that gives rise to (1) a grad-
ally descending ST-segment elevation (remaining <1mm
bove the baseline), followed by a positive T-wave that
esults in a saddle back conﬁguration; (2) normal ﬁndings on
hysical examination; (3) no abnormality in either right or
eft ventricular morphology and/or function demonstrated
y chest radiography and echocardiography; (4) absence of
ther factors, such as ischemia, electrolyte disturbance, or
ypothermia that may have caused the ST-segment abnor-
ality.
Since the criteria of ECG on Brugada syndrome in our
tudy was that J point amplitude over 0.2mV with either
pontaneous or drug-induced type 1 ECG (coved type ST ele-ne or two intercostal spaces above the standard right pre-
ordial leads, we excluded the patients who had type 2 or
ype 3 ECG in control state and then showed still type 2
r type 3 ECG even after pilsicainide test. Therefore, the
on-Brugada group included eight patients who had type 2
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or type 3 ECG in control state and then showed still type 2
or type 3 ECG even after pilsicainide test, or many patients
who had type 1, type 2, or type 3 repolarization pattern with
J point amplitude less than 0.2mV, because they were intro-
duced to our hospital for the suspicion of Brugada syndrome
with unknown etiology of palpitation attack.
The subjects were divided into two groups, the Brugada
group and non-Brugada group. In addition, the subjects were
divided into three subgroups: (1) the symptomatic group
included patients that had a history of documented lethal
VT or VF, or aborted sudden cardiac death; (2) the syncope
group included patients who had episodes related to brain
ischemia such as syncope or fainting, but no documented
arrhythmias at that time; and (3) the asymptomatic group
included patients who had no episodes of documented lethal
ventricular arrhythmia and/or syncope.
All patients then underwent echocardiography while
careful attention was paid to right ventricular enlargement
and/or wall motion abnormalities. Therefore, patients with
apparent organic heart disease or other factors that may
have inﬂuenced ST-segment elevation were excluded. All
patients provided their written informed consent to partic-
ipate in the study, which was approved by the Institutional
Clinical Research and Ethics Committee.
Na+ channel-blocker challenge test (pilsicainide
test)
Na+ channel-blocker challenge tests were performed using
pilsicainide, as previously reported [6]. Pilsicainide was
administered intravenously at 1mg/kg/over 10min with
continuous ECG and non-invasive blood pressure monitor-
ing. During drug administration, 12-lead ECG was recorded
and then the standard right precordial leads (V1—V3), and
3 leads at 1 intercostal space higher than the standard
right precordial leads were recorded using the V4-6 elec-
trodes. Drug administration was immediately stopped when
ST-segment elevation (>5mm), extensive QRS prolongation
(>0.12 s), unfavorable symptoms, and/or frequent ventric-
ular arrhythmias were observed. The test was considered
positive if the coved type ECG pattern (type 1 ECG) appeared
in more than one right precordial lead.
Electrocardiography
Standard 12-lead ECG (ECG-9322, Nihon Kohden Corp.,
Tokyo, Japan) was recorded before and after the admin-
istration of pilsicainide, as previously reported [6]. The J
wave amplitude (V) was analyzed by an organized com-
puter algorithm (ECAPS 12C, Nihon Kohden). In the ECAPS
12C, the terminal point of the QRS (J point) was deﬁned as
the offset point of the QRS waveform determined from the
averaged QRS waveforms from the 12 leads. After the drug
test, the increase in the ST-segment (ST elevation) was
calculated in each of the standard right precordial leads
(V1—V3), one, or two intercostals space above the stan-
dard right precordial leads. The maximum ST elevation
was deﬁned as the maxST elevation.
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ignal averaging
ignal averaging was performed using the signal-averaged
CG (Fukuda Denshi Co. Ltd., FDX-6531, Tokyo, Japan). A
ositive late potential was considered when two of three
riteria (F-QRS >135ms, or LAS40 >39ms, or RMS40 <15V)
ere fulﬁlled.
lectrophysiological stimulation test
he EPS was performed in the fasting state, and all previous
ntiarrhythmic agents had been discontinued for at least
ve half-lives. An intravenous propofol infusion was used to
chieve general anesthesia.
Recordings. A standard 5F decapolar catheter with ten
-mm width electrodes and a 2-mm inter-electrode spacing
as introduced via the right femoral vein or left or right
ubclavian veins. The catheters were positioned in the high
ateral right atrium, His bundle region, coronary sinus, right
entricular (RV) apex and RV outﬂow tract. The 12 lead
urface ECG leads were recorded simultaneously with the
ntracardiac electrograms. The bipolar endocardial electro-
rams were recorded from each of the ﬁve closely spaced
ipolar pairs of electrodes ﬁltered through a 30—400Hz ﬁlter
ith a sampling interval of 1 kHz using a computed electric
ecorder (Cardio LAB v51D, GE Medical Systems, Milwaukee,
I, USA).
Stimulation protocol. Programmed electrical stimulation
as delivered at twice the diastolic threshold at a 2-ms
ulse width. The stimulation protocol for our study included
p to 3 extrastimuli delivered during pacing at drive cycle
engths of 600 and 400ms with a minimum coupling inter-
al of S2S3 180ms at two extrastimuli and of S2S3 and S3S4
00ms at three extrastimuli, and rapid pacing down to a
ycle length of 240ms or 2:1 ventricular response from the
V apex and/or RV outﬂow tract.
When the induced VF lasted for several seconds, we
tarted preparing for cardioversion. Then, the energy was
ischarged after the delivered energy was fulﬁlled. The
esults of the EPS were considered positive only when VF
r sustained ventricular tachycardia lasting 30 s induced.
tatistical analysis
he data are presented as the mean± SD. The ECG data
ere analyzed by paired t-test. The chi-square test for inde-
endence was used for comparisons of the prevalence. A
ested analysis of variance (ANOVA) with the Bonferroni test
as used to compare consecutive data among subgroups.
he chi-square test and Student t-test for independent
ariables were used for comparisons among groups. The
nivariate analysis (Mantel-Haenszel method) and the mul-
ivariate analyses (linear model method) were performed
he software (SPSS 16.0 Family for Windows, Mapinfo, Troy,
Y, USA) to evaluate the association between clinical fac-
ors and the induction of VF. These analyses tested only
ain categories [symptoms, syncope, family history, type
ECG in control, positive in late potential, type 1 ECG after
ilsicainide test, and maxST elevation (200V) after pil-
icainide test]. A value of p < 0.05 was considered to be
tatistically signiﬁcant.
3 N. Sugi et al.
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linical characteristics of the subjects
he study enrolled 77 patients (51± 15 years). The ratio of
ales to females was 8.6 (69/8) in all subjects (Table 1).
here was no signiﬁcant difference in the age (53± 14 years
s. 48± 15 years) or gender (male/female, 42/3 vs. 27/5)
etween the Brugada group and the non-Brugada group. A
amily history was observed in 22% (10/45) of the Brugada
roup and 9% (3/32) of the non-Brugada group, but it did
ot reach a signiﬁcant difference (p = 0.13) between the two
roups.
There were 45 subjects in the Brugada Group and 32 in
he non-Brugada group. The Brugada group contained 8 in
he symptomatic group, 9 in the syncope group and 28 in the
symptomatic group, and the non-Brugada group contained
in the symptomatic group, 13 in the syncope group and 12
n the asymptomatic group (Table 1).
The ratio of males to females in the comprised symp-
omatic patients (symptom/syncope group) of the Brugada
roup (17/0) was signiﬁcantly higher than those of the non-
rugada group (16/4; p = 0.05).
There was no signiﬁcant intra-group difference on the
ncidence of family history in either the Brugada or the non-
rugada group (Table 1).
One patient with symptoms in the non-Brugada group
howed a type 2 ECG in control state and then still showed
ype 2 ECG even after pilsicainide test. Further, another
atient with symptoms in the non-Brugada group had type
repolarization patterns ECG with J point amplitude less
han 0.2mV even after pilsicainide test (maxST elevation
40V). Interestingly, VF was induced during EPS in both
atients. The other ﬁve patients with symptoms in the non-
rugada group had no induction of VF.
lectrophysiological ﬁndings of subjects
n the Brugada group, type 1 ECG was observed in 44% of
he subjects (20/45) and types 1—3 ECG (the repolariza-
ion pattern of type 1, type 2, or type 3 was shown in ECG)
as seen in 60% (27/45) in the control state. Type 1 ECG
as observed in 100% of the patients (45/45) after pilsi-
ainide test and types 1—3 ECG was also observed in 100%.
n the non-Brugada group, ﬁve patients (1 symptoms, 1 syn-
ope, and 3 asymptomatic) with type 2 or 3 ECG in the
ontrol did not show type 1 ECG after pilsicainide test. Thus,
hose ﬁve patients belonged to the non-Brugada group in our
tudy.
The maxST elevation (200V) was seen in 84%
38/45) of the Brugada group, but 0% of the non-Brugada
roup. Positive of late potential was observed in 64%
29/45) of the Brugada group and 25% (8/32) of the non-
rugada group, and there was a signiﬁcant difference
p = 0.0005).There were no signiﬁcant differences in the incidence
f type 1 ECG and types 1—3 ECG in the control and those
fter pilsicainide test, the maxST elevation and positive in
ate potential among the subgroups of patients with Brugada
yndrome (Table 2). T
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Table 2 Clinical characteristics and electrophysiological ﬁndings of the subjects.
Brugada group (n = 45) Non-Brugada group (n = 32)
Symptoma
n (%)
Syncopea
n (%)
Asymptoma
n (%)
Test for
intra-group (p)
Symptoma
n (%)
Syncopea
n (%)
Asymptoma
n (%)
Test for
intra-group (p)
n = 8 n = 9 n = 28 n = 7 n = 13 n = 12
Type 1 ECG in control 5 (56) 3 (33) 12 (43) 0.46 0 (0) 0 (0) 0 (0) —
Types 1—3 ECG in control 6 (75) 4(44) 17 (61) 0.44 1 (14) 1 (8) 3 (25) 0.49
Type 1 ECG after pilsicainide test 8 (100) 9 (100) 28 (100) — 0 (0) 0 (0) 0 (0) —
Types 1—3 ECG after pilsicainide test 8 (100) 9 (100) 28 (100) — 1(14) 3 (23) 3 (25) 0.85
MaxST elevation (200V) 6 (75) 8 (89) 24 (86) 0.70 0 (0) 0 (0) 0 (0) —
Positive in late potential 6 (75) 7 (78) 16 (58) 0.31 1 (14) 4 (31) 3 (25) 0.70
ERP
RV apex at BCL 600ms (ms) 247± 6 233± 13 241± 14 0.21 246± 24 244± 17 244± 21 0.98
RV apex at BCL 400ms (ms) 230± 10 210± 8 221± 11 0.02 222± 19 224± 16 219± 22 0.82
RV outﬂow tract at BCL 600ms (ms) 237± 15 228± 17 235± 11 0.43 255± 31 243± 18 236± 18 0.35
RV outﬂow tract at BCL 400ms (ms) 237± 12 211± 16 225± 15 0.05 225± 31 225± 18 227± 20 0.96
Induction of VF 8 (100) 8 (89) 17 (60) 0.04 1 (14) 3 (23) 0 (0) 0.22
There was no signiﬁcant difference in ERP in the RV apex or in the RV outﬂow at BCLs 600 and 400ms between the Brugada group and the non-Brugada group. Types 1—3 ECG: the
repolarization pattern of type 1, type 2, or type 3 was shown in ECG. Asymptom, asymptomatic; ECG, electrocardiogram; ERP, effective refractory period; RV, right ventricle; BCL, basic
cycle length; VF, ventricular ﬁbrillation.
a Subgroup.
40 N. Sugi et al.
Table 3 Incidence and univariate analysis for the induction of ventricular ﬁbrillation in the control study.
Variables n Incidence Univariate analysis
Number of patients
with induced VF (%)
OR 95% Conﬁdence intervals p
Symptoms 15 10 (67) 2.28 0.70—7.43 0.173
Syncope 22 11 (50) 0.96 0.36—2.59 0.943
Family history 13 8 (62) 1.70 0.50—5.77 0.392
Type 1 ECG in control 20 16 (80) 5.91 1.75—19.96 0.004
Positive in late potential 37 25 (68) 3.87 1.50—9.97 0.005
Type 1 ECG after pilsicainide test 45 34 (76) 16.69 5.17—53.87 0.0001
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lMaxST elevation (200V) 38 30 (79)
Symptoms: documented VF and/or aborted sudden cardiac death;
OR, Mantel-Haenszel odds ratio; ECG, electrocardiogram.
lectrophysiological stimulation test in subjects in
he control state
PS was performed in all subjects. There was no signiﬁ-
ant difference of the ERP in the RV apex at BCL 600ms
239± 13ms vs. 245± 20ms) and 400ms (220± 14ms vs.
20± 17ms) between the Brugada group and non-Brugada
roup. Furthermore, there was no signiﬁcant difference in
he ERP in the RV outﬂow tract at BCL 600ms (234± 15ms
s. 242± 20ms) and 400ms (222± 17ms vs. 226± 20ms)
etween the Brugada group and non-Brugada group. There
as no signiﬁcant difference in the ERP in the RV apex and RV
utﬂow tract at BCL 600 and 400ms among the subgroups of
he Brugada group as well as those of the non-Brugada group
Table 2).
Induction of VF. VF was induced in 73% (33/45) of
atients in the Brugada group and 13% (4/32) of patients
n non-Brugada group. Inducibility of VF was signiﬁcantly
p < 0.0001) higher in Brugada syndrome than non-Brugada
yndrome.
In the Brugada group with induction of VF (n = 33), VFs
ere induced by single ventricular extrastimuli (n = 0, 0%)
nd double ventricular extrastimuli (n = 15, 45%) from RV
pex and/or RV outﬂow tract. Further, VFs were induced by
riple ventricular extrastimuli (n = 18, 55%). VFs were more
requently (p = 0.009) induced by pacing from RV outﬂow
ract (n = 27, 82%) than from RV apex (n = 17, 52%) and they
ere induced by triple ventricular extrastimuli from both
acing sites (n = 11, 33%).
In the non-Brugada group with induction of VF (n = 4), VFs
ere induced by single ventricular extrastimulation (n = 1,
5%) and double ventricular extrastimuli (n = 1, 25%) from
V apex and/or RV outﬂow tract. Further, VFs were induced
y triple ventricular extrastimuli (n = 2, 50%) from the RV
pex (n = 1, 25%), RV outﬂow tract (n = 2, 50%), and both
acing sites (n = 1, 25%). Note that the inducibility of VF
as signiﬁcantly (p = 0.04) different among the subgroups
n the Brugada group, but not the non-Brugada group. The
nducibility of VF (94%, 16/17) in comprised symptomatic
atients (symptomatic and syncope group) of the Brugada
roup was signiﬁcantly (p = 0.008) higher than that (61%,
7/28) in the asymptomatic group of those with Brugada
yndrome.
A univariate test was conducted on the clinical exami-
ations for induction of VF and those results are shown in
t
t
t
s
m12.50 4.25—36.75 0.0001
ope: syncope from unknown etiology; VF, ventricular ﬁbrillation;
able 3. Type 1 ECG after pilsicainide test, the maxST
levation (200V), type 1 ECG in control, and positive
n late potential had relatively high odds ratios and signif-
cance values. However, the multivariate analysis using the
inear regression model evaluated the association between
aseline clinical factors and the induction of VF. The results
re displayed in Table 4, including the odds ratios and
5% conﬁdence intervals. Symptoms indicated the high-
st odds ratio (odds ratio 31.6; 95% conﬁdence interval:
.3—430.6; p = 0.01) followed by type 1 ECG after pil-
icainide test (odds ratio 21.3; 95% conﬁdence interval:
.67—272.3; p = 0.02). Syncope (odds ratio 13.5; 95% con-
dence interval: 1.2—158.8; p = 0.04) also was a signiﬁcant
ariable associated with induced VF. However, a family his-
ory of sudden cardiac death, type I ECG in the control,
ositive of late potential, and maxST elevation (200V)
id not show signiﬁcant association with induction of VF.
ollow-up study
CDs were implanted in 18 patients in the Brugada group
9 symptomatic group, 6 syncope group, 3 asymptomatic
roup) and in 4 in the non-Brugada group (1 symptomatic,
syncope, 0 asymptomatic group). Appropriate shock was
elivered in only one patient of the symptomatic group in
he Brugada group during the average observation period of
3± 14 months. No appropriate shock was delivered to the
est of the patients.
iscussion
ubjects
he subjects in the current study underwent EPS for the
iagnosis of Brugada syndrome or risk stratiﬁcation for
atients who had a family history of Brugada syndrome and
or the further examination of Brugada-like ECG and/or
alpitation and/or syncope. The standard right precordial
eads (V1—V3) and an additional six right precordial leads
hat were located one or two intercostal spaces above
he standard right precordial leads (V1—V3) were used for
he diagnosis of Brugada type ECG because some patients
howed type 1 ECG in additional leads even when nor-
al ECGs were seen in the standard right precordial leads
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Table 4 Multivariate analysis for the induction of ventricular ﬁbrillation in the control study.
Variables n Multivariate analysis
OR 95% Conﬁdence intervals p
Symptoms 15 31.6 2.3—430.6 0.01
Syncope 22 13.5 1.2—158.8 0.04
Family history 13 0.4 0.06—2.8 0.37
Type 1 ECG in control 20 1.3 0.3—6.7 0.76
Positive in late potential 37 1.9 0.5—7.4 0.36
Type 1 ECG after pilsicainide test 45 21.3 1.7—272.3 0.02
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Symptoms: documented VF and/or aborted sudden cardiac dea
electrocardiogram.
(V1—V3) [6]. A Na+ channel-blocker challenge test using pil-
sicainide can unmask intermittent or concealed Brugada
type ECG. However, there is still controversy regarding
whether these drugs are speciﬁc for Brugada syndrome.
Thus, in our study, only type 1 ECG was regarded as Bru-
gada type ECG after the Na+ channel-blocker challenge test
to avoid an overestimate of Brugada syndrome.
Our study showed Brugada syndrome was more com-
mon in males (male:female = 12:1), however, there was no
signiﬁcant difference between the Brugada group and non-
Brugada group.
Family history may be one of the major risk factors for
sudden cardiac death in patients with Brugada syndrome.
In our study, in 22% of the Brugada group had a family his-
tory while 9% of the non-Brugada group did as well. However,
there was no signiﬁcant difference in the prevalence of fam-
ily history among the subgroups of the Brugada group. This
may suggest that family history has a relatively weaker rela-
tionship with the risk of fatal cardiac events than expected,
which is consistent with the ﬁndings of a meta-analysis of
prognostic studies of patients with Brugada syndrome [22].
Gehi et al. [22] suggested that a history of syncope or sud-
den cardiac death, the presence of a spontaneous type 1
Brugada ECG, and male gender predict a more malignant
natural history. They did not recommend the use of a family
history of sudden cardiac death, the presence of an SCN5A
gene mutation, or EPS to guide the management of patients
with a Brugada ECG.
Recently, the Brugada syndrome investigators in Japan
[23] reported that the long-term prognosis of probands in
non-type 1 group was similar to that of type 1 group and
that the presence of early repolarization was also a pre-
dictor of poor outcome, which included only probands with
Brugada-pattern ST-elevation. Note that the criteria of Bru-
gada syndrome in this study was J point amplitude more
than 1mm in the right precordial leads (V1—V3). Those ﬁnd-
ings suggested that it was difﬁcult to discriminate high-risk
patients only by using a standard 12 ECG. Further examina-
tion will be needed to solve this type of issue.Electrophysiological characteristics in patients of
Brugada syndrome
There were no signiﬁcant differences in the incidence of
type 1 ECG and the types 1—3 ECG in the control and those
p
s
m
b
p5.9 0.7—39.3 0.11
yncope: syncope from unknown etiology; OR, odds ratio; ECG,
fter the pilsicainide test, maxST elevation after pilsi-
ainide test and positive in late potential among subgroups
f patients with Brugada syndrome (Table 2). There was no
igniﬁcant difference in the ERPs at the RV apex and RV
utﬂow tract at BCL 600 and 400ms between the Brugada
nd non-Brugada groups, and among the subgroups of the
rugada group as well as those of the non-Brugada group.
The inducibility of VF was signiﬁcantly higher in those
ith Brugada syndrome than the non-Brugada syndrome
atients. This may suggest that the inducibility of VF is help-
ul in identifying individuals at risk of fatal cardiac events,
s noted in previous reports [13,24,25]. However, recent
arge-scale studies [16,17,26] and a meta-analysis [22] on
he prognostic studies of patients with Brugada syndrome
id not support the usefulness of EPS. A low incidence of
rrhythmic events was found in a large Brugada syndrome
opulation [27], with an annual event rate of 2.6% during a
ollow-up of 3 years. The different results may be caused by
he different methods in the stimulation protocol, end-point
etermination, and/or criteria for positive EPS.
The clinical implication of EPS for the risk stratiﬁcation
n patients with ischemic heart disease and low LV ejection
raction is relatively clear [28], but the usefulness of EPS for
he risk stratiﬁcation in patients with a Brugada ECG remains
ontroversial [14,15]. Though the induction of VF during EPS
uggests the existence of electrophysiological substrate of
F, the incidence of spontaneous VF is low in patients with
nduced VF in asymptomatic Brugada syndrome. One of the
easons is that the spontaneous VF in patients with Brugada
yndrome depends mainly on the trigger factors rather than
he existence of substrate. However, the existence of VF
ubstrate is also important. Therefore, variables associated
ith VF induced during EPS in patients without apparent
rganic heart disease also important. If there is no VF sub-
trate, the spontaneous VF never occurs. It is presumed that
egative VF study indicated no risk of VF at that time.
actors of VF induced by EPS
he univariate analysis indicated the induction of VF in
atients without apparent heart disease had a relatively
trong relation with type 1 ECG after pilsicainide test,
axST elevation (200V) and type 1 ECG in control,
ecause those factors had a relatively high incidence in
atients with induction of VF. However, the patients in
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ur study had many complex backgrounds that have some
ffects on induction of VF. Therefore, we should use the
ultivariate analysis to determine what variables were inde-
endently associated with induction of VF during EPS in
atients without organic heart disease.
A linear regression model was used to identify any inde-
endent predictors of the induction of VF during the stimu-
ation test. In this manner, the independent predictive value
f the relative risk to the induction of VF could be assessed.
his analysis showed that symptoms (documented VF and/or
borted sudden cardiac death) had the highest odds ratio.
his result is not inconsistent with the general consideration
hat a history of VF and/or aborted sudden cardiac death is
he strongest variable to indicate the existence of substrate
f VF in patients without apparent heart disease. Syncope
lso showed relatively higher odds ratio. This result is also
ot inconsistent with the general consideration.
Note that type 1 ECG after pilsicainide test also showed
igh odds ratio in a linear regression model, but not type
ECG in control. Type 1 ECG after pilsicainide test, itself,
ndicates the diagnosis of Brugada syndrome in our study,
herefore, the diagnosis of Brugada syndrome itself is strong
ssociation with induction of VF during EPS in patients with-
ut apparent heart disease. Type 1 ECG after pilsicainide
est is superior to type 1 ECG in control for the diagnosis of
rugada syndrome, because pilsicainide unmasks the con-
ealed or intermittent Brugada syndrome. Since the odds
atio shows the relative risk, it is certain that type 1 ECG is
mportant for the diagnosis of Brugada syndrome.
A family history of sudden cardiac death, type 1 ECG in
ontrol, positive of late potential, and maxST elevation
200V) and more did not have signiﬁcant association with
he induction of VF.
These ﬁndings suggested that symptoms, syncope, and
ype 1 ECG after pilsicainide test were independently associ-
ted with the electrophysiological substrate of VF in patients
ithout apparent heart disease.
tudy limitations
here were several limitations to our study. First, the sam-
le sizes in each group were relatively small, because the
ubjects were divided into nine groups on the basis of
rugada type ECG and symptoms related to lethal ventricu-
ar events and/or brain ischemia. Second, long observation
fter EPS was not analyzed, because of infrequency of car-
iac events. Third, a comprehensive genetic screening was
ot performed on all patients. Although this may have been
deal, genetic testing is of uncertain yield and is costly.
onclusions
he electrophysiological characteristics of induced VF
n patients without any apparent organic heart disease
ere assessed. The electrophysiological characteristics in
atients with Brugada type ECG were a high inducibility of
F, relatively lower inducibility of VF in patients with asymp-
omatic patients, and no relationship with the family history.
he multivariate analysis revealed that symptoms, syncope,
nd type 1 ECG after pilsicainide test were independently
ssociated with the inducibility of VF.
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